OBJECTIVES: COVID-19 is a great threat to the modern world and significant threat to immunocompromised patients, including patients with chronic renal failure. We evaluated COVID-19 incidence among our hemodialysis patients and investigated the most probable immune mechanisms against COVID-19. MATERIALS AND METHODS: Başkent University has 21 dialysis centers across Turkey, with 2420 patients on hemodialysis and 30 on peritoneal dialysis. Among these, we retrospectively evaluated 602 patients (257 female/345 male) with chronic renal failure receiving hemodialysis as renal replacement therapy; 7 patients (1.1%) were infected with SARS-CoV-2. We retrospectively collected patient demographic characteristics, clinical data, and immunological factors affecting the clinical course of the disease. We divided patients into groups and included 2 control groups (individuals with normal renal functions): group I included COVID-19-positive patients with normal renal function, group II included COVID-19-positive hemodialysis patients, group III included COVID-19-negative hemodialysis patients, and group IV included COVID-19-negative patients with normal renal function. Lymphocyte subsets in peripheral blood and typing of human leukocyte antigens were analyzed in all groups, with killer cell immunoglobulin like receptor genes analyzed only in COVID-19-positive patients and healthy controls. RESULTS: No deaths occurred among the 7 COVID-19-positive hemodialysis patients. Group I patients were significantly older than patients in groups II and III (P = .039, P = .030, respectively) but not significantly different from group IV (P = .060). Absolute counts of natural killer cells in healthy controls were higherthan in other groups (but not significantly). ActivatedT cells were significantly increased in both COVID-19-positive groups versus COVID-19-negative groups. Groups showed significant differences in C and DQ loci with respect to distribution of alleles in both HLA classes. CONCLUSIONS: Although immunocompromised patients are at greater risk for COVID-19, we found lower COVID-19 incidence in our hemodialysis patients, which should be further investigated in in vitro and molecular studies.
OBJECTIVES: COVID-19 is a great threat to the modern world and significant threat to immunocompromised patients, including patients with chronic renal failure. We evaluated COVID-19 incidence among our hemodialysis patients and investigated the most probable immune mechanisms against COVID-19. MATERIALS AND METHODS: Başkent University has 21 dialysis centers across Turkey, with 2420 patients on hemodialysis and 30 on peritoneal dialysis. Among these, we retrospectively evaluated 602 patients (257 female/345 male) with chronic renal failure receiving hemodialysis as renal replacement therapy; 7 patients (1.1%) were infected with SARS-CoV-2. We retrospectively collected patient demographic characteristics, clinical data, and immunological factors affecting the clinical course of the disease. We divided patients into groups and included 2 control groups (individuals with normal renal functions): group I included COVID-19-positive patients with normal renal function, group II included COVID-19-positive hemodialysis patients, group III included COVID-19-negative hemodialysis patients, and group IV included COVID-19-negative patients with normal renal function. Lymphocyte subsets in peripheral blood and typing of human leukocyte antigens were analyzed in all groups, with killer cell immunoglobulin like receptor genes analyzed only in COVID-19-positive patients and healthy controls. RESULTS: No deaths occurred among the 7 COVID-19-positive hemodialysis patients. Group I patients were significantly older than patients in groups II and III (P = .039, P = .030, respectively) but not significantly different from group IV (P = .060). Absolute counts of natural killer cells in healthy controls were higherthan in other groups (but not significantly). ActivatedT cells were significantly increased in both COVID-19-positive groups versus COVID-19-negative groups. Groups showed significant differences in C and DQ loci with respect to distribution of alleles in both HLA classes. CONCLUSIONS: Although immunocompromised patients are at greater risk for COVID-19, we found lower COVID-19 incidence in our hemodialysis patients, which should be further investigated in in vitro and molecular studies.
Authors: Adem Tuncer; Sami Akbulut; Adil Baskiran; Ezgi Erdal Karakas; Deniz Yavuz Baskiran; Brian Carr; Sezai Yilmaz Journal: J Gastrointest Cancer Date: 2021-02-18
Authors: Ivan Yanev; Michael Gagnon; Matthew P Cheng; Steven Paraskevas; Deepali Kumar; Alice Dragomir; Ruth Sapir-Pichhadze Journal: Can J Kidney Health Dis Date: 2021-09-14
Authors: Matthew J Weiss; Laura Hornby; Farid Foroutan; Sara Belga; Simon Bernier; Mamatha Bhat; C Arianne Buchan; Michael Gagnon; Gillian Hardman; Maria Ibrahim; Cindy Luo; Me-Linh Luong; Rahul Mainra; Alex R Manara; Ruth Sapir-Pichhadze; Sarah Shalhoub; Tina Shaver; Jeffrey M Singh; Sujitha Srinathan; Ian Thomas; Lindsay C Wilson; T Murray Wilson; Alissa Wright; Allison Mah Journal: Transplant Direct Date: 2021-09-07
Authors: Federico Alberici; Stefania Affatato; Daniele Moratto; Raffaele Badolato; Luigi D Notarangelo; Marco Chiarini; Francesco Scolari; Federica Mescia; Elisa Delbarba; Alice Guerini; Martina Tedesco; Peter D Burbelo; Roberta Zani; Ilaria Castagna; Agnese Gallico; Mattia Tonoli; Margherita Venturini; Aldo M Roccaro; Mauro Giacomelli; Jeffrey I Cohen; Viviana Giustini; Kerry Dobbs; Helen C Su; Chiara Fiorini; Virginia Quaresima; Fabio Battista Viola; Valerio Vizzardi; Mario Gaggiotti; Nicola Bossini; Paola Gaggia Journal: J Nephrol Date: 2022-01-24 Impact factor: 4.393